Sergei A. Goncharenko

Sergei A. Goncharenko

Auto-generated profile, based on publicly available information

Sergei A. Goncharenko

Samara State Medical University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2022 in Science and Innovations in Medicine
Verified
Journal Article
Open access
PDF file
LVLarisa Volova
Larisa Volova
NONatalya Ossina
Natalya Ossina
SKSergei I. Kuznetsov
Sergei I. Kuznetsov
OGOksana A. Gusyakova
Oksana A. Gusyakova
Denis G. AlekseevDenis G. Alekseev
Denis G. Alekseev
КИКузнецов Сергей Иванович
Кузнецов Сергей Иванович
Aim – to study the immunomodulator-induced individual cytokine production by peripheral blood mononuclear cells (PBMCs) and to evaluate the potential of using this approach as a universal cellular test system in personalized medicine. Material and methods. The peripheral blood mononuclear cells given by donors were cultured in vitro in the presence of immunomodulators Imunofan and Polyoxidonium. After incubation, the enzyme-linked immunosorbent assay (ELISA) of the culture medium for the presence of pro-inflammatory cytokines IL-6, IL-8/CXCL8, MCP-1/CCL2, and IFN-α cytokines was performed. Results. The results of the experiment have demonstrated the absence of spontaneous or immunomodulator-induced production of IFN-α by PBMCs. These data correspond to the information presented earlier in the scientific literature. We also observed a pronounced inhibitory effect of both immunomodulators on the production of cytokines MCP-1/CCL2, IL-6, IL-8/CXCL8 by PBMCs, along with the individual variability of their production and the cumulative effect of production over time. Conclusion. The features of the production of pro-inflammatory cytokines by PBMCs into the medium in the presence of immunomodulators, revealed by the in vitro screening, can be used to develop universal in vitro cellular test systems for personalized diagnosis of a number of socially significant inflammatory and autoimmune diseases.

20 April 2025 in Perm Medical Journal
Verified
Journal Article
Open access
PDF file
YBYu. N. Battalova
Yu. N. Battalova
MPM. A. Postnikov
M. A. Postnikov
SCS. E. Chigarina
S. E. Chigarina
LVLarisa Volova
Larisa Volova
NON. K. Osina
N. K. Osina
SGS. A. Goncharenko
S. A. Goncharenko
Objective. To study the anti-inflammatory effects of the “Alvostaz-sponge” medical product for the treatment of chronic periodontitis. Materials and methods. The culture of juvenile human dermal fibroblasts was treated with TNF-α (1st series of experiments) and a mixture of TNF-α with “Alvostaz-sponge” extract (2nd series of experiments). The concentration of cytokines IL-6, MCP-1 in the culture medium of fibroblasts was assessed using enzyme immunoassay (ELISA). The examination and treatment of 74 patients (49 women and 25 men), with a diagnosis of chronic generalized periodontitis of moderate severity were carried out. Results. In response to TNF-α stimulated inflammation, fibroblasts sharply increased the production of both chemokine MCP-1 and the inflammatory mediator IL-6 into the culture medium. A dose-dependent rise of “Alvostaz-sponge” extract content in the culture medium correlated with a decrease in the concentration of MCP-1, which indicates a pronounced inhibitory effect of “Alvostaz-sponge” extract on the production of MCP-1 cytokine. An increase in the concentration of IL-6 correlated with a dose-dependent increase in the extract of “Alvostaz sponge” in the culture medium of TNF-α-stimulated fibroblasts. Conclusions. The results of the study demonstrated “Alvostaz-sponge” medication to be a powerful inhibitor of chemokine MCP-1 production and, it is due to this effect that it restricts the monocyte cells migration into the periodontal pocket zone. The obtained results of the treatment show accelerated healing of the periodontal complex when using the “Alvostaz-sponge” remedy.

14 October 2026 in Science and Innovations in Medicine
Verified
Journal Article
Open access
Denis G. AlekseevDenis G. Alekseev
Denis G. Alekseev
LVLarisa Volova
Larisa Volova
ВТВолова Лариса Теодоровна
Волова Лариса Теодоровна
NRNikolay Ryabov
Nikolay Ryabov
РАРябов Николай Анатольевич
Рябов Николай Анатольевич
КАКарякина Ольга Анатольевна
Карякина Ольга Анатольевна
Background. By-products of human donor plasma fractionation often possess untapped potential for regenerative medicine. However, they are frequently excluded from further technological processing, and a comprehensive physicochemical and biological characterization remains lacking – a gap that hinders the development of novel, effective biomaterials. Objective. To perform an integrated physicochemical and biological analysis of fibrinogen-containing precipitate No. 1 (FР No. 1) – a by-product of donor plasma fractionation – and to evaluate its potential as a raw material for biomedical applications. Materials and Methods. A multi-method approach was employed, including Fourier-transform infrared (FTIR) spectroscopy, UV spectrophotometry, scanning electron microscopy (SEM), SDS‑PAGE electrophoresis, quantitative determination of protein mass fraction, assessment of fibrinogen extraction yield in citrate buffer and phosphate-buffered saline (37 °C, 5 hours), as well as in vitro biological testing on human dermal fibroblast cultures. Results. FP No. 1 was found to preserve the structural integrity of fibrinogen with low levels of impurities. The lyophilizate formed porous fibrin matrices with pore sizes ranging from 100 to 180 μm. Cell viability upon contact with the material reached 96.5 % (p 0.05), confirming the absence of cytotoxicity. The protein mass fraction in the dry substance was 77 %. Under optimal extraction conditions, the fibrinogen yield reached 21.9 % (citrate buffer) and 21.5 % (phosphate-buffered saline). Conclusion. FP No. 1 represents a highly promising secondary protein raw material for the development of bioinks for 3D bioprinting, wound dressings, and tissue-engineered constructs. These findings strongly advocate for the rational reintegration of plasma fractionation by‑products into high‑technology biomedical applications.